3.1 Receptor Pharmacology & Autonomic Nervous System

3.1 Receptor Pharmacology & Autonomic Nervous System

Quick Reference: Receptor pharmacology defines how drug molecules interact with biological targets to produce therapeutic or toxic responses. Understanding ligand-receptor kinetics, dose-response relationships, and autonomic nervous system (ANS) neurotransmission is essential for predicting pharmacological responses and managing clinical toxicity.

Pharmacodynamics describes what a drug does to the body, focusing on receptor binding, signal transduction, and physiological response. The autonomic nervous system provides the classic anatomical framework for studying receptor subtypes, agonist activity, and antagonist blockade.

---

Principles of Receptor Interactions & Pharmacodynamics

Drugs exert pharmacological effects by interacting with macromolecular targets, primarily cell-surface or intracellular receptors, ion channels, enzymes, and carrier proteins. The interaction between a drug ($D$) and a receptor ($R$) follows reversible mass-action kinetics:

$$D + R \rightleftharpoons DR \rightarrow \text{Effect}$$

Quantitative Parameters

• Affinity ($K_d$): The equilibrium dissociation constant, defined as the drug concentration at which 50% of total receptors are occupied. $K_d$ is inversely proportional to affinity; a lower $K_d$ value indicates higher binding affinity.
• Potency ($EC_{50}$): The molar concentration of a drug required to produce 50% of its maximal physiological effect. Potency depends on both affinity ($K_d$) and tissue coupling efficiency.
• Efficacy ($E_{max}$): The maximum response obtainable by a drug when all available receptors are occupied or maximum intracellular signaling is achieved. Efficacy reflects intrinsic activity ($\alpha$).

---

Agonists, Partial Agonists, and Antagonists

Ligands are classified based on their intrinsic activity ($\alpha$), which describes their capacity to activate a receptor upon binding.

Ligand Classifications

1. Full Agonists ($\alpha = 1$): Bind to and fully stabilize the active receptor conformation ($R^*$), eliciting the maximal biological response ($E_{max}$) achievable by the tissue.
2. Partial Agonists ($0 < \alpha < 1$): Bind to receptors but induce submaximal stabilization of $R^*$, resulting in a ceiling effect ($E_{max}$ lower than full agonists) even at 100% receptor occupancy.
   • Clinical Significance: In the absence of a full agonist, partial agonists act as agonists. In the presence of a full agonist, partial agonists act as competitive antagonists by occupying receptors and lowering the overall physiological response (e.g., buprenorphine at $\mu$-opioid receptors, pindolol at $\beta$-adrenoceptors).
3. Competitive Antagonists ($\alpha = 0$): Bind reversibly to the active site of the receptor without inducing activation. They prevent agonist binding.
   • Dose-Response Effect: Causes a parallel rightward shift of the log concentration-response curve (increases $EC_{50}$) without reducing $E_{max}$. The antagonism is surmountable by increasing agonist concentration.
4. Non-Competitive & Irreversible Antagonists: Bind either irreversibly via covalent bonds to the active site (e.g., phenoxybenzamine at $\alpha$-receptors) or allosterically to a distinct site.
   • Dose-Response Effect: Decreases $E_{max}$ (depresses maximal response) and cannot be surmounted by adding more agonist. $EC_{50}$ may remain unchanged.
5. Inverse Agonists ($\alpha < 0$): Bind preferentially to the inactive receptor state ($R$), suppressing constitutive (basal) receptor activity in systems with spontaneous signaling (e.g., GABA-A receptor inverse agonists).

Therapeutic Index & Margin of Safety

The Therapeutic Index (TI) quantifies drug safety:

$$\text{Therapeutic Index (TI)} = \frac{TD_{50}}{ED_{50}} \quad \text{or} \quad \frac{LD_{50}}{ED_{50}}$$

Where $TD_{50}$ is the median toxic dose, $LD_{50}$ is the median lethal dose, and $ED_{50}$ is the median effective dose. A wider TI indicates a safer drug profile.

---

The Autonomic Nervous System (ANS): Organization & Neurotransmitters

The ANS regulates involuntary visceral functions through two main efferent divisions: the Sympathetic Nervous System (SNS) (thoracolumbar origin; fight-or-flight) and the Parasympathetic Nervous System (PNS) (craniosacral origin; rest-and-digest).

Neurotransmission Summary

• Preganglionic Neurons (All ANS): Release Acetylcholine (ACh) acting on Nicotinic ($N_N$) ionotropic receptors at autonomic ganglia.
• Parasympathetic Postganglionic Neurons: Release ACh acting on Muscarinic ($M_1-M_5$) metabotropic receptors on target tissues.
• Sympathetic Postganglionic Neurons: Predominantly release Norepinephrine (NE) acting on $\alpha$- and $\beta$-adrenoceptors. Exceptions include sweat glands (release ACh acting on $M_3$) and renal vascular smooth muscle (release Dopamine acting on $D_1$).
• Adrenal Medulla: Chromaffin cells function as modified postganglionic sympathetic neurons, releasing Epinephrine (80%) and Norepinephrine (20%) directly into systemic circulation.

---

Autonomic Receptor Subtypes & Signal Transduction

---

Sympathomimetic & Parasympathomimetic Pharmacology

Sympathomimetics

• Direct-Acting Agonists:

  • Adrenaline (Epinephrine): Non-selective $\alpha_1, \alpha_2, \beta_1, \beta_2$ agonist. First-line for anaphylaxis (1:1000 IM, 0.5mg in adults), severe croup, and cardiac arrest.
  • Noradrenaline (Norepinephrine): Potent $\alpha_1, \alpha_2, \beta_1$ agonist with minimal $\beta_2$ activity. First-line vasopressor for septic shock to increase systemic vascular resistance (SVR).
  • Salbutamol (Albuterol) & Salmeterol: Selective $\beta_2$ agonists used as short-acting (SABA) and long-acting (LABA) bronchodilators in asthma and COPD.
  • Phenylephrine: Selective $\alpha_1$ agonist used as a nasal decongestant and vasopressor for spinal anesthesia hypotension.
  • Clonidine & Dexmedetomidine: Central $\alpha_2$ agonists reducing sympathetic tone, used in hypertension, ADHD, opioid withdrawal, and ICU sedation.

• Indirect-Acting Sympathomimetics:

  • Amphetamine & Tyramine: Displace stored norepinephrine from presynaptic vesicles into the synaptic cleft.
  • Cocaine & Atomoxetine: Inhibit the norepinephrine transporter (NET), blocking NE reuptake.

Parasympathomimetics

• Direct Muscarinic Agonists:

  • Bethanechol: $M_3$-selective agonist used for non-obstructive urinary retention and neurogenic bladder.
  • Pilocarpine: $M_3$ agonist used topically for open-angle glaucoma (induces miosis and trabecular meshwork drainage) and orally for xerostomia (Sjögren's syndrome).

• Reversible Acetylcholinesterase (AChE) Inhibitors:

  • Neostigmine & Pyridostigmine: Quaternary ammonium compounds that increase synaptic ACh; used in Myasthenia Gravis and reversal of non-depolarizing neuromuscular blockade.
  • Donepezil, Galantamine, Rivastigmine: CNS-penetrating AChE inhibitors used to manage mild-to-moderate Alzheimer's dementia.
  • Edrophonium: Short-acting AChE inhibitor historically used in the Tensilon test for Myasthenia Gravis diagnosis.

• Irreversible Organophosphates & Toxicology:

  • Organophosphate insecticides (e.g., malathion, parathion) and nerve agents (sarin) irreversibly phosphorylate the AChE esteratic site.
  • Presentation: Cholinergic crisis—DUMBBELSS (Diarrhea, Urination, Miosis, Bronchospasm/Bradycardia, Emesis, Lacrimation, Salivation, Sweating) plus muscle fasciculations and paralysis.
  • Treatment: Atropine (blocks muscarinic manifestations) + Pralidoxime (2-PAM) (reactivates AChE by cleaving organophosphate-enzyme bond before 'aging' occurs).

---

Anticholinergic Agents & Clinical Toxicology

Muscarinic receptor antagonists competitively block ACh actions at parasympathetic neuroeffector junctions.

Key Muscarinic Antagonists

• Atropine: Tertiary amine muscarinic antagonist; used for severe symptomatic bradycardia, organophosphate poisoning, and pre-operative inhibition of secretions.
• Hyoscine (Scopolamine): Crosses blood-brain barrier; used as a transdermal patch for motion sickness and end-of-life respiratory secretions ("death rattle").
• Ipratropium & Tiotropium: Quaternary ammonium SAMA and LAMA inhalers used in COPD and acute severe asthma; minimal systemic absorption.
• Oxybutynin, Solifenacin, Tolterodine: $M_3$-selective antagonists used for overactive bladder and urge incontinence.

Anticholinergic Toxidrome

Excessive anticholinergic blockade (e.g., atropine, tricyclic antidepressants, diphenhydramine overdose) presents with the classic clinical mnemonic:

• "Dry as a bone" (Anhidrosis, dry mucous membranes)
• "Blind as a bat" (Mydriasis, loss of accommodation/cycloplegia)
• "Red as a beet" (Cutaneous vasodilation/flushing)
• "Hot as a hare" (Hyperthermia due to loss of sweating)
• "Mad as a hatter" (Delirium, hallucinations, agitation)
• Bowel and bladder lose their tone (Paralytic ileus, urinary retention)

Management: Supportive care, cooling, urinary catheterization. In severe central toxicity, administer the tertiary AChE inhibitor Physostigmine.